Skip to main content

Table 3 Primary reasons for treatment discontinuation – from chart review

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

Primary reason for treatment discontinuation First line (N = 220a) Second line (N = 236a) Third line (N = 113a)
n, (%) n, (%) n, (%)
Disease progression 168 (76.4%) 169 (71.6%) 57 (50.4%)
Total completion of treatment 31 (14.1%) 30 (12.7%) 7 (6.2%)
Toxicities or side effects 14 (6.4%) 8 (3.4%) 7 (6.2%)
Patient choice (non-financial) 4 (1.8%) 8 (3.4%) 5 (4.4%)
Financial reasons 1 (0.5%) 1 (0.4%) 1 (0.9%)
Drug resistance 2 (0.9%) 0 (0.0%) 1 (0.9%)
Patient physical status 0 (0.0%) 2 (0.8%) 1 (0.9%)
Death related to mBC 0 (0.0%) 5 (2.1%) 3 (2.7%)
Death not related to mBC 0 (0.0%) 2 (0.8%) 1 (0.9%)
Treatment still ongoing 0 (0.0%) 11 (4.7%) 30 (26.5%)
  1. There were more agents than patients per line (e.g. 220 agents vs. 178 patients in first line) as physicians were asked to provide reasons of discontinuation for every single agent rather than for every therapy
  2. mBC metastatic breast cancer
  3. aNumber of agents